PROCEPT BioRobotics

69 articles about PROCEPT BioRobotics

• PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas

  4/4/2024

  PROCEPT BioRobotics® Corporation, a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced it will host an in-person investor event on Friday, May 3, 2024, at the Grand Hyatt Hotel in San Antonio, TX at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time.

• PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results

  2/27/2024

  PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023.

• PROCEPT BioRobotics to Present at the 44th Annual TD Cowen Health Care Conference in Boston

  2/12/2024

  PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 44th Annual TD Cowen Health Care Conference in Boston.

• PROCEPT BioRobotics® Announces Preliminary Fourth Quarter Revenue of $43.3 million to $43.6 million

  1/8/2024

  PROCEPT BioRobotics Corporation, a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2023.

• PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

  11/1/2023

  PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2023.

• PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

  10/16/2023

  PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023.

• The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation

  10/12/2023

  PROCEPT BioRobotics® Corporation, a surgical robotics global leader, is pleased to announce that the National Institute for Health and Care Excellence has bestowed its strongest endorsement, the "standard arrangements" recommendation, on Aquablation® therapy for the treatment of benign prostatic hyperplasia.

• PROCEPT BioRobotics Announces New Corporate Headquarters in San Jose

  9/20/2023

  PROCEPT BioRobotics® Corporation, a surgical robotics company focused on developing transformative solutions in urology, proudly announces the grand opening of its state-of-the-art global corporate headquarters in San Jose, California.

• PROCEPT BioRobotics® Receives U.S. FDA Investigational Device Exemption to Investigate Aquablation® Therapy for Prostate Cancer

  9/12/2023

  PROCEPT BioRobotics Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today the Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to investigate the safety and efficacy of Aquablation therapy for prostate cancer.

• PROCEPT BioRobotics® Announces First Commercial Aquablation Therapy Procedures in Japan

  8/22/2023

  PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a global leader in surgical robotics, announced today that it has successfully completed the first commercial Aquablation® therapy procedures in Japan.

• PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston

  8/17/2023

  PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2023 Wells Fargo Healthcare Conference in Boston.

• PROCEPT BioRobotics Corporation Announces Pricing of Upsized Offering of Common Stock

  8/2/2023

  PROCEPT BioRobotics® Corporation announced the pricing of an upsized underwritten public offering of 4,422,169 shares of its common stock at a public offering price of $33.92 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $150 million.

• PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock

  8/1/2023

  PROCEPT BioRobotics® Corporation announced the commencement of an underwritten public offering of $125,000,000 of shares of its common stock.

• PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

  7/27/2023

  PROCEPT BioRobotics Corporation today reported unaudited financial results for the quarter ended June 30, 2023.

• Five-Year Data from the WATER II Study Demonstrate Aquablation Therapy Delivers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms while Preserving Sexual Function in Men with Large Prostates

  4/28/2023

  PROCEPT® BioRobotics Corporation announced that 5-year results from the WATER II Study demonstrate that Aquablation therapy, a minimally invasive, robotic, surgical treatment for benign prostatic hyperplasia, safely and effectively provides durable symptom relief and preserves sexual function out to five years for men with large prostates.

• PROCEPT BioRobotics Reports First Quarter 2023 Financial Results and Increases 2023 Revenue Guidance

  4/27/2023

  PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2023.

• PROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las Vegas

  4/5/2023

  PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2023 before market open on Thursday, April 27, 2023.

• PROCEPT BioRobotics Corp. Announces Investor Event at 2023 AUA Annual Meeting in Chicago

  3/30/2023

  PROCEPT® BioRobotics Corporation announced it will host an in-person investor event on Friday, April 28, 2023, in Chicago at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time.

• Aquablation Therapy is the first surgical robotics system to receive a MedTech Innovation Briefing (MIB) from the National Institute for Health Care Excellence

  3/7/2023

  PROCEPT® BioRobotics Corporation today announced Aquablation Therapy received a MedTech Innovation Briefing (MIB) from the National Institute for Health Care Excellence (NICE), for benign prostate hyperplasia (BPH) in the United Kingdom.

• PROCEPT BioRobotics Corp. to Present at the Virtual Key Bank Life Sciences & MedTech Investor Forum

  3/2/2023

  PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”) today announced that members of management will present at the upcoming Virtual Key Bank Life Sciences & MedTech Investor Forum. Management is scheduled to present on Tuesday, March 21 at 12:45 p.m. Eastern Time.